Research programme: acute myeloid leukaemia therapeutics - Critical Outcome Technologies

Drug Profile

Research programme: acute myeloid leukaemia therapeutics - Critical Outcome Technologies

Alternative Names: AML tyrosine kinase inhibitors - Critical Outcome Technologies

Latest Information Update: 16 Apr 2013

Price : $50

At a glance

  • Originator Critical Outcome Technologies
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 09 Apr 2013 Critical Outcome Technologies selects and patents three drug candidates selected for preclinical studies in Acute myeloid leukaemia
  • 24 Jan 2012 Preclinical trials in Acute myeloid leukaemia in Canada (unspecified route)
  • 29 Jun 2010 Critical Outcome Technologies receives non-repayable funding from the National Research Council of Canada Industrial Research Assistance Program for development of Acute myeloid leukaemia therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top